Mostrar el registro sencillo del ítem

Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015

dc.contributor.advisorUribe Pérez, Claudia Janeth
dc.contributor.advisorSerrano Gómez, Sergio Eduardo
dc.contributor.authorDíaz Bueno, Pedro Antonio
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2000-2015spa
dc.date.accessioned2021-08-19T22:07:23Z
dc.date.available2021-08-19T22:07:23Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/20.500.12749/13926
dc.description.abstractEl sarcoma de Kaposi es un tumor angioproliferativo poco frecuente etiológicamente vinculado al virus herpes humano tipo 8 y asociado a inmunosupresión. Clínicamente se reconocen 4 subtipos, en los cuales observamos que pueden presentar compromiso a nivel cutáneo y/o visceral. Algunos de ellos pueden tener un crecimiento lento, localizado o indolente, pero pueden llegar a diseminarse y/o crecer rápidamente y causar morbilidad y mortalidad significativa. Desde su primer reporte en 1872, observamos que el sarcoma de Kaposi presentó un aumento las tasas de incidencia asociado a la epidemia del VIH hacia los años 80´s, con posterior descenso con el advenimiento de la terapia antirretroviral(1,2). Actualmente se reconocen tasas de supervivencia a 5 años que van desde el 38% al 72% de acuerdo a si el compromiso es extenso o localizado, respectivamente(2). Sin embargo, en Colombia, y específicamente en Santander, no se ha encontrado hasta la fecha ningún estudio que aporte datos locales sobre el comportamiento de este tumor en nuestra población. Por lo anterior, teniendo en cuenta la importancia de esta patología, la falta de estudios a nivel nacional que caractericen o demuestren una asociación entre las variables clínicas con la sobrevida y el impacto de la obtención de estos datos y su aplicabilidad en los modelos de atención, promoción y prevención de tumores malignos, se decide realizar este estudio retrospectivo tomando los datos del registro poblacional de cáncer del área metropolitana de Bucaramanga de los años, con el objetivo de determinar las variables sociodemográficas que impactan en la sobrevida del paciente, obteniendo datos importantes como la incidencia del sarcoma de Kaposi en el área metropolitana, la tasa de sobrevida de esta población, el grado de asociación con las diferentes variables entre otros.spa
dc.description.tableofcontents1. RESUMEN DEL PROYECTO: ......................................................................... 7 2. DESCRIPCIÓN DEL PROYECTO ...................................................................... 9 2.1 Planteamiento del problema y justificación .............................................. 9 2.2 Marco teórico.............................................................................................. 10 2.2.1 Definición ............................................................................................... 10 2.2.2 Epidemiología ........................................................................................ 10 2.2.3 Fisiopatogenia ....................................................................................... 13 2.2.4 Características clínicas .......................................................................... 14 2.2.5 Diagnóstico ............................................................................................ 16 2.2.6 Pronóstico y prevención ......................................................................... 17 2.2.7 Tratamiento ............................................................................................ 19 2.3 Estado del arte ........................................................................................... 20 2.4 Objetivos del estudio ................................................................................. 23 2.4.1 Objetivo general ..................................................................................... 23 2.4.2 Objetivos específicos ............................................................................. 23 2.5 Metodología ................................................................................................ 23 2.5.1. Criterios de inclusión ............................................................................. 23 2.5.2. Criterios de exclusión: ........................................................................... 23 2.5.3. Cálculo de tamaño de muestra y muestreo: ......................................... 23 2.5.4. Mecanismo de recolección de la información ....................................... 23 2.5.6 Definición de variables ........................................................................... 24 2.6 Plan de análisis de datos: ......................................................................... 26 2.7 Consideraciones éticas: ............................................................................ 27 3. RESULTADOS ............................................................................................... 28 3.1 Descripción de la cohorte ......................................................................... 28 3.2 Desenlaces ................................................................................................. 31 3.3 Análisis de supervivencia ......................................................................... 32 4. DISCUSIÓN .................................................................................................... 39 5. CONCLUSIONES ........................................................................................... 41 6. BIBLIOGRAFÍA .............................................................................................. 42spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleAnálisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015spa
dc.title.translated5-year survival analysis of patients with kaposi sarcoma in the metropolitan area of ​​Bucaramanga between the years 2000-2015spa
dc.degree.nameEspecialista en Dermatologíaspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Dermatologíaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsDermatologyspa
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsKaposi's sarcomaspa
dc.subject.keywordsAngioproliferative tumorspa
dc.subject.keywordsNeoplasmsspa
dc.subject.keywordsBiometricsspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.relation.references1. Kaposi M. Idiopathisches multiples Pigmentsarkom. Docent an der Univ Wien. 1872;1(27):265–73spa
dc.relation.references2. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Prim [Internet]. 2019;5(1). Available from: http://dx.doi.org/10.1038/s41572-019-0060-9spa
dc.relation.references3. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med. 1996;2(8):925–7spa
dc.relation.references4. Chan RKW, Chio MTW, Koh Y. Manifestaciones cutáneas de infección por el VIH [Internet]. Cuarta edi. Bolognia J, Schaffer J, Cerroni L, editors. Dermatología. Madrid: Elsevier Espa8#241;a, S.L.U.; 2018. 1364–1382 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00078-4spa
dc.relation.references5. Kaye KM. Virus herpes asociado al sarcoma de Kaposi (virus herpes humano de tipo 8) [Internet]. Octava. Bennett J, Dolin R, Blaser M, editors. Mandell, Douglas y Bennett. Enfermedades infecciosas. Principios y práctica. Elsevier Espa8#241;a, S.L.U.; 2016. 1868–1873 p. Available from: http://dx.doi.org/10.1016/B978-84-9022-917-0/00143-8spa
dc.relation.references6. Cattani P, Cerimele F, Porta D, Graffeo R, Ranno S, Marchetti S, et al. Agespecific seroprevalence of human herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect [Internet]. 2003 Apr 1 [cited 2020 Jul 7];9(4):274–9. Available from: https://pubmed.ncbi.nlm.nih.gov/12667236/spa
dc.relation.references7. Angeloni A, Heston L, Uccini S, Sirianni MC, Cottoni F, Masala MV, et al. High Prevalence of Antibodies to Human Herpesvirus 8 in Relatives of Patients with Classic Kaposi’s Sarcoma from Sardinia. J Infect Dis [Internet]. 1998 Jun [cited 2020 Jul 7];177(6):1715–8. Available from: https://pubmed.ncbi.nlm.nih.gov/9607855/spa
dc.relation.references8. Mohanna S, Ferrufino JC, Sanchez J, Bravo F, Gotuzzo E. Epidemiological and clinical characteristics of classic Kaposi’s sarcoma in Peru. J Am Acad Dermatol [Internet]. 2005 [cited 2020 Jul 7];53(3):435–41. Available from: https://pubmed.ncbi.nlm.nih.gov/16112349/spa
dc.relation.references9. AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clin Infect Dis. 2017;65(8):1316–26.spa
dc.relation.references10. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al. SEER Cancer Statistics Review 1975-2007 National Cancer Institute SEER Cancer Statistics Review 1975-2007 National Cancer Institute. Cancer. 2019.spa
dc.relation.references11. Instituto Nacional De Salud. Boletín Epidemiológico Semanal -BES-, Colombia 2019. Ministerio de salud. 2019.spa
dc.relation.references12. Jiménez K, Martínez JD, Hernández G, Garzón MA, Hormaza N, Lizarazo JI, et al. Three varieties of Kaposi’s sarcoma with gastrointestinal involvement. Rev Colomb Gastroenterol. 2015;30(3):342–6spa
dc.relation.references13. Downing C, Mendoza N, Sra K. 80 - Virus del herpes humanos [Internet]. Fourth Edi. DermatologÃ-a. Elsevier Espa8#241;a, S.L.U.; 2019. 1400–1424 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00080-2spa
dc.relation.references14. Sternbach G, Varon J. Moritz Kaposi: Idiopathic pigmented sarcoma of the skin. J Emerg Med [Internet]. 1995 [cited 2020 Jul 8];13(5):671–4. Available from: https://pubmed.ncbi.nlm.nih.gov/8530789/spa
dc.relation.references15. North PE. Neoplasias y proliferaciones seudoneoplásicas vasculares [Internet]. Cuarta edi. Bolognia J, Schaffer J, Cerroni L, editors. Dermatología. Madrid: Elsevier Espa8#241;a, S.L.U.; 2018. 2020–2049 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00114-5spa
dc.relation.references16. Antman K, Chang Y. Kaposi ’s Sarcoma. N Engl J Med. 2000;342(14):1027– 38spa
dc.relation.references17. Cai Q, Verma SC, Lu J, Robertson ES. Molecular Biology of Kaposi’s Sarcoma-associated Herpesvirus and Related Oncogenesis [Internet]. 1st ed. Vol. 78, Advances in Virus Research. Elsevier Inc.; 2010. 87–142 p. Available from: http://dx.doi.org/10.1016/B978-0-12-385032-4.00003-3spa
dc.relation.references18. Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019;58(5):538–42spa
dc.relation.references19. Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation [Internet]. Vol. 42, Seminars in Oncology. W.B. Saunders; 2015 [cited 2020 Jul 12]. p. 247–57. Available from: https://pubmed.ncbi.nlm.nih.gov/25843729/spa
dc.relation.references20. Corey C. Virology, epidemiology, and transmission of human herpesvirus 8 infection - UpToDate [Internet]. Uptodate. [cited 2020 Jul 12]. Available from: https://www-uptodate-com.aure.unab.edu.co/contents/virology-epidemiologyand-transmission-of-human-herpesvirus-8-infection?search=sarcoma de kaposi&topicRef=7726&source=see_linkspa
dc.relation.references21. Krown S, Chadha J. Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis - UpToDate [Internet]. Uptodate. 2019 [cited 2020 Jul 12]. Available from: https://www-uptodatecom.aure.unab.edu.co/contents/classic-kaposi-sarcoma-epidemiology-riskfactors-pathology-and-molecular-pathogenesis?search=sarcoma de kaposi&topicRef=7729&source=see_linkspa
dc.relation.references22. Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma [Internet]. Vol. 18, American Journal of Clinical Dermatology. Springer International Publishing; 2017 [cited 2020 Jul 8]. p. 529–39. Available from: /pmc/articles/PMC5509489/?report=abstractspa
dc.relation.references23. Kandemir NO, Gun BD, Bahadir B, Yurdakan G, Ozdemir N, Karadayi N, et al. C-Kit (CD117) expression in classic Kaposi’s sarcoma: Experimental dermatology. Clin Exp Dermatol [Internet]. 2010 Jul [cited 2020 Jul 12];35(5):525–30. Available from: https://pubmed.ncbi.nlm.nih.gov/19874361spa
dc.relation.references24. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol [Internet]. 2008 May [cited 2020 Jul 7];21(5):572–82. Available from: https://pubmed.ncbi.nlm.nih.gov/18376387/spa
dc.relation.references25. Requena C, Alsina M, Morgado-Carrasco D, Cruz J, Sanmartín O, SerraGuillén C, et al. Kaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment. Actas Dermosifiliogr [Internet]. 2018;109(10):878–87. Available from: https://doi.org/10.1016/j.ad.2018.06.013spa
dc.relation.references26. Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C. Clinical features and course of kaposi’s sarcoma in kidney transplant patients: Report of 13 cases. Am J Nephrol [Internet]. 1994 [cited 2020 Jul 15];14(2):121–6. Available from: https://pubmed.ncbi.nlm.nih.gov/8080004/spa
dc.relation.references27. Shepherd FA, Maher E, Cardella C, Cole E, Greig P, Wade JA, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol [Internet]. 1997 [cited 2020 Jul 15];15(6):2371–7. Available from: https://pubmed.ncbi.nlm.nih.gov/9196152spa
dc.relation.references28. Groopman J. AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis - UpToDate [Internet]. Uptodate. 2018 [cited 2020 Jul 15]. Available from: https://www-uptodate-com.aure.unab.edu.co/contents/aids-relatedkaposi-sarcoma-clinical-manifestations-and-diagnosis?search=sarcoma de kaposi&topicRef=7729&source=see_linkspa
dc.relation.references29. Ackerman AB. Subtle clues to diagnosis by conventional microscopy. The patch stage of Kaposi’s sarcoma. Am J Dermatopathol [Internet]. 1979 [cited 2020 Jul 18];1(2):165–72. Available from: https://pubmed.ncbi.nlm.nih.gov/549492/spa
dc.relation.references30. O’Donnell PJ, Pantanowitz L, Grayson W. Unique histologic variants of cutaneous Kaposi sarcoma. Am J Dermatopathol [Internet]. 2010 May [cited 2020 Jul 18];32(3):244–50. Available from: https://pubmed.ncbi.nlm.nih.gov/20075709/spa
dc.relation.references31. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol [Internet]. 2008 [cited 2020 Jul 18];3(1). Available from: https://pubmed.ncbi.nlm.nih.gov/18655700/spa
dc.relation.references32. Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah AA, Selivanova G, et al. HHV-8/KSHV during the development of Kaposi’s sarcoma: Evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol [Internet]. 2005 Jan [cited 2020 Jul 18];32(1):21–7. Available from: https://pubmed.ncbi.nlm.nih.gov/15660651/spa
dc.relation.references33. Bishop BN, Lynch DT. Cancer, Kaposi Sarcoma [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30521260spa
dc.relation.references34. Bishop BN, Lynch DT. Cancer, Kaposi Sarcoma [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2020 Nov 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30521260spa
dc.relation.references35. Marušić Z, Billings SD. Histopathology of Spindle Cell Vascular Tumors [Internet]. Vol. 10, Surgical Pathology Clinics. W.B. Saunders; 2017 [cited 2020 Aug 18]. p. 345–66. Available from: https://pubmed.ncbi.nlm.nih.gov/28477885spa
dc.relation.references36. Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of african children: Evidence for at least 2 patterns of KSHV transmission. J Infect Dis [Internet]. 2009 Aug 1 [cited 2020 Aug 18];200(3):430–8. Available from: /pmc/articles/PMC3975590/?report=abstractspa
dc.relation.references37. Moosa MR. Kaposi’s sarcoma in kidney transplant recipients: A 23-year experience. QJM - Mon J Assoc Physicians [Internet]. 2005 Mar [cited 2020 Aug 18];98(3):205–14. Available from: https://pubmed.ncbi.nlm.nih.gov/15728402spa
dc.relation.references38. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS [Internet]. 2009 Aug 24 [cited 2020 Aug 18];23(13):1701–6. Available from: https://pubmed.ncbi.nlm.nih.gov/19550283spa
dc.relation.references39. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy. Cancer [Internet]. 2010 Aug 15 [cited 2020 Aug 18];116(16):3969–77. Available from: https://pubmed.ncbi.nlm.nih.gov/20564162spa
dc.relation.references40. Delyon J, Bizot A, Battistella M, Madelaine I, Vercellino L, Lebbé C. PD-1 blockade with nivolumab in endemic Kaposi sarcoma [Internet]. Vol. 29, Annals of Oncology. Oxford University Press; 2018 [cited 2020 Aug 18]. p. 1067–9. Available from: https://pubmed.ncbi.nlm.nih.gov/29324995spa
dc.relation.references41. Lundgren JD, Melbye M, Pedersen C, Rosenberg PS, Gerstoft J. Changing patterns of kaposi’s sarcoma in danish acquired immunodeficiency syndrome patients with complete follow-up. Am J Epidemiol [Internet]. 1995 Apr 1 [cited 2020 Nov 18];142(7):652–8. Available from: https://pubmed.ncbi.nlm.nih.gov/7702040/spa
dc.relation.references42. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi’s sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol [Internet]. 1993 [cited 2020 Nov 18];28(3):371– 95. Available from: https://pubmed.ncbi.nlm.nih.gov/8445054spa
dc.relation.references43. Franceschi S, Arniani S, Balzi D, Geddes M. Survival of classic Kaposi’s sarcoma and risk of second cancer. Br J Cancer. 1996;74(11):1812–4.spa
dc.relation.references44. Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 2002;98(6):916–22.spa
dc.relation.references45. Lodi S, Guiguet M, Costagliola D, Fisher M, De Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102(11):784–92spa
dc.relation.references46. Sen F, Tambas M, Ciftci R, Toz B, Kilic L, Bozbey HU, et al. Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma. J Dermatolog Treat. 2016;27(3):275–7.spa
dc.relation.references47. Royse KE, El Chaer F, Amirian ES, Hartman C, Krown SE, Uldrick TS, et al. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. PLoS One. 2017;12(8):1–12spa
dc.relation.references48. Vivek K, Parita S, Mohit G, Arsalan T, Abhinav B. Racial disparities in incidence & survival of Kaposi’s sarcoma in the United States Vivek. Indian J Med Res [Internet]. 2019;354–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23144490spa
dc.relation.references49. Saldarriaga-Cantillo A, Bravo LE, Londoño Ó, García LS, Collazos P. Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi’s sarcoma in Cali, Colombia. Colomb Med. 2012;43(4):273–80spa
dc.relation.references50. Levi F. Cancer incidence in five continents, vol. VI. Vol. 29, European Journal of Cancer. 1993. 2315–2319 pspa
dc.relation.references51. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Collazos T, et al. Reliable information for cancer control in Cali, Colombia. Colomb Med [Internet]. 2018 [cited 2021 Jun 8];49(1):23–34. Available from: /pmc/articles/PMC6018818/spa
dc.relation.references52. Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi’s sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: A critical review of an old disease [Internet]. Vol. 9, International Journal of Infectious Diseases. Elsevier; 2005 [cited 2020 Jul 7]. p. 239–50. Available from: https://pubmed.ncbi.nlm.nih.gov/16095940spa
dc.relation.references53. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol. 2008;21(5):572–82spa
dc.relation.references54. Oncologia C. Survival and Prognostic Factors of Kaposi ’ s Sarcoma Patients Treated at a High Complexity Oncology Care Center. 2020;66(3).spa
dc.relation.references55. Klingenberg RE, Esser S, Brockmeyer NH, Michalik C, Skaletz-Rorowski A, Potthoff A. Profile of Kaposi sarcoma patients in the competence network HIV/AIDS. Hautarzt. 2018;69(2):143–8.spa
dc.relation.references56. Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32(5):409–14spa
dc.contributor.cvlacUribe Pérez, Claudia Janeth [0000267848]spa
dc.contributor.cvlacSerrano Gómez, Sergio Eduardo [0001521095]spa
dc.contributor.orcidSerrano Gómez, Sergio Eduardo [0000-0001-6418-7116]spa
dc.contributor.researchgateUribe Pérez, Claudia Janeth [Claudia-Janeth-Uribe-Perez-2157369946]spa
dc.subject.lembDermatologíaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembMedicinaspa
dc.subject.lembNeoplasmasspa
dc.subject.lembBiometríaspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishKaposi's sarcoma is a rare angioproliferative tumor etiologically linked to human herpes virus type 8 and associated with immunosuppression. Clinically, 4 subtypes are recognized, in which we observe that they may present skin and / or visceral involvement. Some of them may be slow, localized or indolent growth, but they can spread and / or grow rapidly and cause significant morbidity and mortality. Since its first report in 1872, we observed that Kaposi's sarcoma presented an increase in the incidence rates associated with the HIV epidemic towards the 1980s, with a subsequent decrease with the advent of antiretroviral therapy (1,2). Currently, 5-year survival rates ranging from 38% to 72% are recognized according to whether the involvement is extensive or localized, respectively (2). However, in Colombia, and specifically in Santander, no study has been found to date that provides local data on the behavior of this tumor in our population. Therefore, taking into account the importance of this pathology, the lack of studies at the national level that characterize or demonstrate an association between clinical variables with survival and the impact of obtaining these data and their applicability in care models , promotion and prevention of malignant tumors, it was decided to carry out this retrospective study taking data from the population registry of cancer of the metropolitan area of ​​Bucaramanga of the years, with the aim of determining the sociodemographic variables that impact on the survival of the patient, obtaining important data such as the incidence of Kaposi's sarcoma in the metropolitan area, the survival rate of this population, the degree of association with the different variables, among others.spa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalSarcoma de kaposispa
dc.subject.proposalTumor angioproliferativospa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.description.learningmodalityModalidad Presencialspa


Ficheros en el ítem

Thumbnail
Nombre:
2021_Tesis_Pedro_Diaz_Bueno.pdf
Tamaño:
647.0Kb
Formato:
PDF
Descripción:
Tesis
Ver/
Thumbnail
Nombre:
2021_Licencia_Pedro_Diaz_Bueno.pdf
Tamaño:
133.5Kb
Formato:
PDF
Descripción:
Licencia
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia